The FDA’s Office of New Drugs is being “bombarded” by data and decision-making is suffering as a result. They aren’t alone in this challenge.

As you consider more efficient approaches for monitoring, searching, and distributing results to the pharmacovigilance team, here’s one information manager’s advice.